PubMed HealthSearch

PubMed · 3005780

Progress in pediatric solid tumors.

Abstract

Since 1980, impressive progress in the treatment of solid tumors has altered the practice of pediatric surgical oncology. Because these advances have been balanced by both liberal and conservative viewpoints, an accurate reassessment of traditional approaches has been possible. Noteworthy alterations in chemotherapy, radiation therapy, and surgical attitudes have improved survival rates and lessened the morbidity associated with malignant disease. Close cooperation among surgeons, pediatricians, and oncologists remains the common denominator in the successful treatment of pediatric solid tumors. This article presents examples of progress in the treatment of Hodgkin's disease, metastatic pulmonary disease, Wilms' tumor, and rhabdomyosarcoma and discusses the role of surgical intervention in conjunction with chemotherapy and radiation therapy.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B H Kaufman. 1986. Progress in pediatric solid tumors.. https://doi.org/10.1016/s0025-6196(12)61929-6

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Adjuvant therapy for primary breast cancer in a female patient affected by autoimmune liver disease: does it cure breast cancer and primary biliary cirrhosis?

Polychemotherapy (CMF or CMF-like regimens) is the treatment of choice in premenopausal breast cancer patients with 1-3 positive nodes. In clinical practice, patients with abnormal biochemical tests of liver function are usually excluded from this potentially curative methotrexate-containing regimen in order to avoid worsening of hepatic damage. On the other hand, recent reports have shown a beneficial effect of methotrexate in a particular autoimmune liver disease such as primary biliary cirrhosis. We discuss the case of a female patient with breast cancer and primary biliary cirrhosis whose biochemical tests of liver function and the titer of antimitochondrial antibody persistently improved after treatment with 3 cycles of CMF. In conclusion, we suggest that the CMF regimen is potentially useful in patients with breast cancer and primary biliary cirrhosis.

Antineoplastic Combined Chemotherapy Protocols